Benitec Biopharma Ltd ADR (BNTC) — Cash Flow-to-Debt Ratio
Benitec Biopharma Ltd ADR (BNTC) has a Cash Flow-to-Debt Ratio of -1.14x as of December 2025, meaning its operating cash flow of $-3.78 Million could theoretically repay -1% of its total liabilities ($3.32 Million) in one year. Check Benitec Biopharma Ltd ADR cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Benitec Biopharma Ltd ADR Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Benitec Biopharma Ltd ADR across 13 annual periods. Also explore BNTC asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Benitec Biopharma Ltd ADR (2013–2025)
Year-by-year debt coverage analysis for Benitec Biopharma Ltd ADR. For market capitalisation and broader financial context, see Benitec Biopharma Ltd ADR market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -10.27x | $-23.59 Million | $2.30 Million | ▼ -162.6% |
| 2024 | -3.91x | $-19.40 Million | $4.96 Million | ▲ +7.5% |
| 2023 | -4.23x | $-18.01 Million | $4.26 Million | ▲ +17.8% |
| 2022 | -5.14x | $-15.90 Million | $3.09 Million | ▲ +45.1% |
| 2021 | -9.37x | $-12.83 Million | $1.37 Million | ▼ -87.3% |
| 2020 | -5.00x | $-7.54 Million | $1.51 Million | ▼ -375.5% |
| 2019 | 1.82x | $4.79 Million | $2.64 Million | ▲ +140.5% |
| 2018 | -4.49x | $-8.55 Million | $1.91 Million | ▲ +51.8% |
| 2017 | -9.32x | $-8.30 Million | $891.40K | ▲ +63.7% |
| 2016 | -25.70x | $-20.21 Million | $786.36K | ▼ -233.9% |
| 2015 | -7.70x | $-9.69 Million | $1.26 Million | ▼ -22.8% |
| 2014 | -6.27x | $-9.69 Million | $1.55 Million | ▲ +41.1% |
| 2013 | -10.64x | $-9.27 Million | $871.53K | — |